Loading…
science
Hosted by Dr. Neil Love · science · EN · 161 episodes
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
35%
Guest openness
Selective
Sign up to generate a grounded pitch for Hematologic Oncology Update.
Signup to Generate a PitchHematologic Oncology Update is a science podcast hosted by Dr. Neil Love, with 161 episodes on record and a Required Pod Score of 80.
Dr. Neil Love hosts Hematologic Oncology Update, a science show with 161 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #101
Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Treatment (1:33) Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36) CME information and select publications
Episode #100
Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Therapy (2:48) Relapsed/Refractory Disease (39:30) CME information and select publications
Episode #98
Featuring an interview with Dr Douglas W Sborov, including the following topics: DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00) Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26) Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36) Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48) Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00) Prevention and management of ophthalmic events related to treatment with belamaf (21:27) Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49) Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27) Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53) CME information and select publications
Episode #97
Featuring an interview with Prof Andreas Hochhaus, including the following topics: Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00) Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09) Potential mechanisms of adverse events documented with TKIs (10:23) Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23) Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14) Comparative efficacy of asciminib and other agents used to treat CML (40:01) Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53) Practical care strategies for CML patients; future developments (52:32) CME information and select publications
Episode #96
Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics: Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00) Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48) Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29) CME information and select publications
Recent guests on Hematologic Oncology Update. Study who booked and why before you pitch.
Sponsor detection runs nightly. Check back soon.
Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
